Core Viewpoint - Changchun Gaoxin (000661) is collaborating with Danish company ALK-Abelló A/S to develop specific immunotherapy products for house dust mite (HDM) allergens, which includes both subcutaneous and sublingual formulations [1] Group 1: Product Information - The house dust mite allergen preparation (Antodada) is a subcutaneous immunotherapy product that is already commercially available [1] - The sublingual tablet (ACARIZAX) is the world's first approved sublingual immunotherapy tablet for allergic asthma and allergic rhinitis, having received regulatory approval in multiple countries including Europe and the US [1] - ACARIZAX is currently being applied in the Greater Bay Area of China and the Boao Lecheng Medical Pilot Zone, with clinical research ongoing in China [1]